论文部分内容阅读
观察免疫缺陷(损)者口服胸腺肽结肠溶制剂后的临床免疫学效果。方法:应用流式细胞术(FCM)对50~65岁正常中老年人作外用血T淋巴细胞免疫表型(亚群)的测试普查,用自身对照方法,观察总结筛选的14例免疫缺陷(损)者在口服胸腺肽结肠溶制剂后外周血T细胞亚群分布的变化。结果:日服胸腺肽15 mg即可有意义地促进免疫缺陷者CD_3、CD_4及CD_8/CD_8比值的提升,其中CD_4和CD_4/CD_8比值与用药前相比,有非常显著性差异(P<0.01)。结论:临床日服剂量 15mg胸腺肽即相当于其注射剂的用量范围,表明口服胸腺肽结肠溶制剂与注射剂的临床效果相当。
To observe the clinical immunological effects of immunodeficient (thymosin) -based oral administration of thymosin and colonic agents. Methods: We used flow cytometry (FCM) to test the immunophenotype (subpopulation) of peripheral blood T lymphocytes in normal middle-aged and elderly people aged 50-65 years. Using self-control method, we observed 14 cases of immunodeficiency Changes in the distribution of T lymphocyte subsets in peripheral blood after oral administration of thymosin colonic-lytic agents. Results: Thymosin 15 mg daily increased the ratio of CD_3, CD_4 and CD_8 / CD_8 in immunocompromised patients. The ratio of CD_4 and CD_4 / CD_8 was significantly different from that before treatment (P <0. 01). Conclusion: Clinical daily dose of 15mg thymosin is equivalent to the range of dosage of its injection, indicating that oral thymosin colonic dissolution and injection of the clinical effect is quite.